Residual disease-guided strategy combining ibrutinib and venetoclax for the treatment of relapsed or refractory chronic lymphocytic leukemia

被引：0
|
作者：
Stocker, Nicolas
机构：
来源：
HEMATOLOGIE | 2022年 / 28卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：174 / 175
页数：2
相关论文
共 50 条
  • [41] Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia
    Shustik, C.
    Bence-Bruckler, I.
    Delage, R.
    Owen, C. J.
    Toze, C. L.
    Coutre, S.
    ANNALS OF HEMATOLOGY, 2017, 96 (07) : 1185 - 1196
  • [42] Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmuniotheraphy
    Soumerai, Jacob D.
    Ni, Ai
    Darif, Mohamed
    Londhe, Anil
    Xing, Guan
    Mun, Yong
    Kay, Neil E.
    Shanafelt, Tait D.
    Chaffee, Kari G.
    Furman, Richard R.
    Hillmen, Peter
    Sharman, Jeff
    Seymour, John F.
    Chanan-Khan, Asher A.
    Byrd, John C.
    Jones, Jeffrey A.
    Ferrante, Lucille A.
    Dreiling, Lyndah K.
    Mobasher, Mehrdad
    Stark, Thomas
    Reddy, Vijay
    Howes, Angela J.
    James, Danelle
    Bhargava, Pankaj
    Zelenetz, Andrew D.
    BLOOD, 2018, 132
  • [43] Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax
    Waldron, Madeline
    Winter, Allison
    Hill, Brian T.
    CLINICAL PHARMACOKINETICS, 2017, 56 (11) : 1255 - 1266
  • [44] Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax
    Madeline Waldron
    Allison Winter
    Brian T. Hill
    Clinical Pharmacokinetics, 2017, 56 : 1255 - 1266
  • [45] Ibrutinib combined with venetoclax treatment outcome in chronic lymphocytic leukemia: A systematic review
    Sugianto, Jeremy Octavian
    Purushotama, Nyoman Bagus Satcitta Ananda
    Ontowirjo, Yudi Ali Putra
    Sutanto, Mario
    Kurniawan, Andree
    ANNALS OF ONCOLOGY, 2023, 34 : S1447 - S1447
  • [46] Venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia
    Yang, Lin
    Banerji, Versha
    LANCET ONCOLOGY, 2024, 25 (04) : 413 - 414
  • [47] Combination of ibrutinib and venetoclax in first-line treatment of chronic lymphocytic leukemia
    Stocker, Nicolas
    HEMATOLOGIE, 2022, 28 (01): : 12 - 13
  • [48] Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
    Handunnetti, Sasanka
    Anderson, Mary Ann
    Roberts, Andrew W.
    Davids, Matthew S.
    Ma, Shuo
    Boyer, Michelle
    Arzt, Jennifer
    Al Masud, Abdullah
    Popovic, Relja
    Jacobson, Amanda
    Kim, Su Y.
    Seymour, John F.
    EJHAEM, 2021, 2 (02): : 266 - 271
  • [49] Outcomes of Ibrutinib Therapy Given after Prior Venetoclax Therapy in Ibrutinib-Naive Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Brown, Jennifer R.
    Davids, Matthew S.
    Chang, Julie
    Ma, Shuo
    Biondo, Juliana
    Mobasher, Mehrdad
    Mun, Yong
    Mato, Anthony R.
    BLOOD, 2018, 132
  • [50] Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
    Davids, Matthew S.
    Hallek, Michael
    Wierda, William
    Roberts, Andrew W.
    Stilgenbauer, Stephan
    Jones, Jeffrey A.
    Gerecitano, John F.
    Kim, Su Young
    Potluri, Jalaja
    Busman, Todd
    Best, Andrea
    Verdugo, Maria E.
    Cerri, Elisa
    Desai, Monali
    Hillmen, Peter
    Seymour, John F.
    CLINICAL CANCER RESEARCH, 2018, 24 (18) : 4371 - 4379
12345